@debmaskens.bsky.socialCommend this initiative to describe patient-relevant deterioration of #Qol during (and long after) adjuvant tx. See this often in #rcc #kidneycancer
Were patient co-authors involved? Those with lived experience?
#ppi #patientengagement
#cansky
@ikccorg.bsky.social๐
1 October 2026
๐ 12:00โ13:15
๐ European Parliament, Brussels
Hosted by MEP Tilly Metz and MEP Romana Jerkovic.
#KidneyCancer #EUHealth #CancerPolicy #EUCancerPlan #EuropeanParliament
@actionkidneycancer.bsky.socialPlease help #kidneycancer patients, the IKCC patient survey is now open.
Take 15minutes to complete the survey, your experiences will help shape kidney cancer care for the next decade.
For more info and complete the survey please follow the link:
actionkidneycancer.org/get-involved...
@dengyuemedicine.bsky.socialKidney cancer progressed after immunotherapy? ๐งฌ
FDA approved belzutifan (Weliregยฎ) + lenvatinib (Lenvimaยฎ) on Sept 28 for advanced clear cell RCC after PD-1/PD-L1 therapy: the first HIF-2ฮฑ inhibitor + VEGFR-TKI combo for these patients.
@kidneycan.bsky.socialBoth clinical and translational research play an important role in advancing our understanding of #KidneyCancer. And the two often work hand in hand. What researchers learn in the lab can help shape clinical studies, while observations from patients can lead to new questions.
@actionkidneycancer.bsky.socialIf you or a family member have been diagnosed with #kidneycancer our Patient support forum is a place where you can share your experience and concerns with other people who understand the emotional and physical effects of kidney cancer.
Find out more:
actionkidneycancer.org/hel.../patie...
@erneurogen.bsky.socialFive ERNs, one consensus. ๐ ERN eUROGEN, ERKNet, ERN-EYE, Endo ERN, & ERN GENTURIS are developing shared guidance for treating VHL-associated #KidneyCancer with Belzutifan:
๐ Read more: eurogen-ern.eu/urology-week...
@journals.sagepub.comThis #UrologyWeek, learn more about Kidney Cancer: The Silent Cancer.
Why do some people develop long-term kidney problems after kidney cancer surgery? This study identifies factors that may help guide follow-up care and monitoring.
@hqip.bsky.socialDid you see the latest report on #KidneyCancer from @nkca-natcan.bsky.social @natcan-news.bsky.social @hqip.bsky.social โ
This audit of care received by people diagnosed with kidney cancer examines diagnosis, surgery and systemic treatment.
@achtungamerica.bsky.socialThe FDA has approved belzutifan (Welireg) in combination with lenvatinib (Lenvima) for the treatment of adult patients with advanced clear cell renal cell carcinoma (ccRCC) following progression on a PD-1 or PD-L1 inhibitor. #kidneycancer
www.cancernetwork.com/view/belzuti...
@oncoalert.bsky.socialFDA ๐บ๐ธ News: LITESPARK-011 Update in #kidneyCancer
Source: FDA
On September 24, 2026, the FDA๐บ๐ธ approved belzutifan plus lenvatinib for adults with advanced renal cell carcinoma containing a clear cell component after PD-1/PD-L1 inhibitor treatment. In the LITESPARK-011
@kidneycan.bsky.socialOn World Cancer Research Day, KidneyCAN & the International Kidney Cancer Coalition have launched the Global Patient Survey on Kidney Cancer! All #KidneyCancer patients, carers, & survivors are invited to share their experiences.
@kidneycan.bsky.socialHappy #WorldCancerResearchDay! In #KidneyCancer, research has transformed our understanding of the disease and continues to open new possibilities for diagnosis, treatment, and care. But there is still more to learn and more progress to make.
@actionkidneycancer.bsky.socialOur colleague @Pointonsupport has released the latest episode of the Living with and beyond Cancer podcast.
This weeks guest is Jemma Falloon, who was diagnosed with #KidneyCancer & Thyroid Cancer on the same day.
Listen to Jemma's inspirational story:
actionkidneycancer.org/.../patient-...
@ikccorg.bsky.social๐ Your experience matters. Share your voice and help shape the future of kidney cancer care. The survey takes around 15 minutes to complete: bit.ly/IKCC_Kidney_...
#KidneyCancer #KidneyCancerResearch #GlobalPatientSurvey #PatientVoice #CancerResearch
@ikccorg.bsky.socialRegistration via this form is required: buff.ly/D6QbkCR
@kidneycan.bsky.socialKidneyCAN Advocacy Days would not be possible without the generous support of our sponsors. Thank you to the organizations helping make it possible for #KidneyCancer advocates to bring the needs of the kidney cancer community directly to policymakers.
@ikccorg.bsky.socialOur September newsletter is here! ๐
Discover the latest from the global kidney cancer community, including the launch of the 5th Global Patient Survey, research updates, global collaborations and more.
Read it here: buff.ly/8SEi5gE
@kidneycan.bsky.socialThe progress we've made didn't happen by accident. It was made possible by researchers pursuing new discoveries, patients participating in research, and advocates making sure #KidneyCancer remains part of the conversation in Washington.